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Abstract
 
In autoimmune polyglandular syndromes (APS), several organ-specific autoimmune diseases
are clustered. Although APS type I is caused by loss of central tolerance, the etiology of APS
type II (APS-II) is currently unknown. However, in several murine models, depletion of
CD4
 
 
 
 CD25
 
 
 
 regulatory T cells (T
 
regs
 
) causes a syndrome resembling human APS-II with
multiple endocrinopathies. Therefore, we hypothesized that loss of active suppression in the
periphery could be a hallmark of this syndrome. T
 
regs
 
 from peripheral blood of APS-II, control
patients with single autoimmune endocrinopathies, and normal healthy donors showed no
differences in quantity (except for patients with isolated autoimmune diseases), in functionally
important surface markers, or in apoptosis induced by growth factor withdrawal. Strikingly,
APS-II T
 
regs
 
 were defective in their suppressive capacity. The defect was persistent and not due
to responder cell resistance. These data provide novel insights into the pathogenesis of APS-II
and possibly human autoimmunity in general.
Key words: suppressor cells • autoimmune polyendocrinopathies • Addison’s disease • 
type I diabetes • autoimmune thyroiditis
 
Introduction
 
Autoimmunity is largely prevented by central and peripheral
mechanisms of immunological tolerance. Mechanisms of
peripheral tolerance can be further divided into active and
passive regulation (1). One prominent mechanism of active
peripheral tolerance has recently been reappreciated; that is,
suppression of autoreactivity by specialized lymphocytes
(2). Although they have been preferentially called regulatory
T cells (T
 
regs
 
) instead of suppressor T cells, their primary
function is to suppress. Among several suppressor cells, murine
CD4
 
 
 
 CD25
 
 
 
 T
 
regs
 
 have recently been characterized exten-
sively (2). They are naturally anergic in vitro, but can expand
in vivo (3). They suppress innate (4) as well as adaptive
immunity, including memory (5). Their mode of suppression
is not yet fully delineated, but forkhead transcription factor
FOXP3 is required (6–8). Mutations in FOXP3 cause a
severe inflammatory syndrome in children called IPEX
(immunodysregulation, polyendocrinopathy, enteropathy,
and X-linked syndrome) or X-linked autoimmunity-allergic
disregulation syndrome (9).
The human counterparts comprise 5–15% of peripheral
CD4
 
 
 
 T cells and are usually tested in in vitro coculture
assays with CD4
 
 
 
 CD25
 
 
 
 responder cells (10–13). They
can mediate infectious tolerance (10, 13). They are highly
susceptible to apoptosis induced by growth factor withdrawal
(14), and their suppressive capacity is most potent in the
CD25
 
high
 
-expressing fraction (15). Several other groups have
also generated valid data on the physiology of human T
 
regs
 
using conventional CD4
 
 
 
 CD25
 
 
 
 T
 
regs
 
 (5, 11, 12, 14, 16).
Murine T
 
regs
 
 have been associated recently with various
beneficial or detrimental effects in different models (i.e.,
down-regulation of autoimmunity, allergy, graft-versus-
host disease, but also of immunity to tumors and infections;
references 2, 17). However, CD4
 
 
 
 CD25
 
 
 
 T
 
regs
 
 were ini-
tially discovered by Sakaguchi et al. in a distinct model of
murine autoimmunity (18). After ex vivo depletion of
CD4
 
 
 
 CD25
 
 
 
 T cells, mice developed autoimmunity to
multiple organs. Remarkably, most of the target organs are
endocrine glands; therefore, they largely resemble autoim-
mune polyglandular syndrome type II (APS-II) in humans.
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Human APS is characterized by multiple endocrine dis-
eases initiated by an autoimmune process in the same pa-
tient (19, 20). Early onset APS-I (also called autoimmune
polyendocrinopathy-candidiasis-ectodermal dystrophy syn-
drome or APECED) is caused by a defect in central toler-
ance due to mutations in the autoimmune regulator AIRE
(21) and includes Addison’s disease and hypoparathyroid-
ism along with susceptibility to mucocutaneous candidiasis
(19, 20). The hallmark of adult onset APS-II is the com-
bined occurrence of two or more of the following autoim-
mune endocrinopathies: Addison’s disease, type I diabetes,
or autoimmune thyroid disease (19, 20). Aside from the as-
sociation with polymorphisms in CTLA-4 and an HLA-
extended haplotype, the pathogenesis of APS-II is currently
unknown (19, 20, 22). Due to the striking similarities with
the autoimmune phenotype of mice depleted of CD4
 
 
 
CD25
 
 
 
 T cells (18), we hypothesized that a defect of these
cells must be a central component of the human syndrome.
Therefore, we analyzed CD4
 
 
 
 CD25
 
 
 
 T cells phenotypi-
cally and functionally from patients with APS-II, control
patients, and normal healthy donors.
 
Materials and Methods
 
Study Subjects. 
 
All APS-II and control patients were diag-
nosed by clinical and laboratory parameters, including autoanti-
bodies against target tissues after long-standing disease. In addi-
tion, all patients were followed up for possible occurrence of
additional autoimmune endocrine diseases. Specifically, control
patients with Addison’s disease had TSH values within the nor-
mal range during their last visit (TSH 0.75 
 
 
 
U/ml for patient 3
and TSH 1.56 
 
 
 
U/ml for patient 6; normal values for TSH are
0.3–3.5 
 
 
 
U/ml). Screening for antithyroid peroxidase, antithyro-
globulin, and antiislet antibodies were negative. All patients were
well controlled on hormone replacement therapy, which was
their only medication during the study period. None of the APS-
II patients exhibited hypoparathyroidism, skin or gastrointestinal
comorbidity, immunodeficiency, candidiasis, or enamel hypopla-
sia clearly differentiating them from APS-I. IPEX could also be
excluded due to onset, clinical differences, and female prepon-
derance of our patients. Patients’ age, combinations of endocrine
diseases, and duration of each disease are shown in Table I. Nor-
mal healthy subjects from the area were recruited for voluntary
blood donations. The age range of normal healthy donors was
24–60 yr with a mean age of 36 yr. Any normal donor or patient
with signs or symptoms of infection or systemic immune activa-
tion was excluded before the study. All study subjects agreed on
blood donation solely for the purpose of research according to
guidelines of the university’s ethical committee.
 
Antibodies and Reagents. 
 
Culture medium, OKT-3, and
PHA were used as described previously (23). 1 
 
 
 
g/ml anti-
CD28 mAb 9.3 was a gift from Bristol Myers Squibb. For
FACS
 
®
 
 analysis, the following conjugated antibodies were used:
CD4 and HLA-DR (Immunotech); CD28, CD25, CTLA-4,
and CD95 (BD Biosciences); and PD-1 (eBioscience). TGF
 
 
 
was obtained from IQ Products, and glucocorticoid-induced
TNF receptor (GITR) was obtained from R&D Systems. Iso-
type controls (IgG1 and IgG2a) were also obtained from Immu-
notech. FITC-conjugated annexin V (Roche) in propidium
iodide (Sigma-Aldrich) containing buffer was used for quantifi-
cation of apoptosis.
 
Isolation of CD4
 
 
 
 CD25
 
 
 
 and CD25
 
 
 
 T Cells. 
 
PBMCs
were isolated from heparinized peripheral blood by Ficoll-
Hypaque (BAG) density gradient centrifugation. CD4
 
 
 
 T cells
were isolated from PBMCs with a negative CD4
 
 
 
 T cell isolation
kit obtained from Miltenyi Biotec according to the manufac-
turer’s protocol. Purity was routinely confirmed by flow cyto-
metric analysis (
 
 
 
95% CD4
 
 
 
) and also by the lack of prolifera-
tion to 1 
 
 
 
g/ml PHA. Similarly, CD4
 
 
 
 CD25
 
 
 
 and CD25
 
 
 
 T
cells were separated from pure, untouched CD4
 
 
 
 T cells using
CD25 microbeads (Miltenyi Biotec).
 
Isolation of CD4
 
 
 
 CD25
 
high
 
 T Cells. 
 
CD4
 
 
 
 T cells were iso-
lated as aforementioned. The CD25
 
high
 
-expressing fraction was
further separated from the CD25
 
low
 
 and CD25
 
 
 
 cells by flow cyto-
metric sorting using CD4-FITC– and CD25-PE–labeled antibod-
ies. Sorting was performed with a MoFlo machine (DakoCytoma-
tion). Purity of CD25
 
high
 
-expressing CD4
 
 
 
 T cells was 100%.
 
Cell Proliferation Assays. 
 
5 
 
 
 
 10
 
3
 
 cells were incubated for
7 d. In all proliferation assays, irradiated (3,000 gray) PBMCs
were used as feeder cells at a ratio of 10:1. [
 
3
 
H]Thymidine uptake
and incorporation into genomic DNA were used to quantify cel-
lular proliferation as described previously (23).
 
Flow Cytometric Analysis. 
 
Detection of various markers and
quantification of apoptosis as described in the Results and Dis-
cussion sections were performed using an EPICS XL™ flow cy-
tometer (Beckman Coulter). Cells were stained with different
combinations of FITC- and PE-conjugated mAbs and their ap-
propriate isotype controls. T cells were incubated for 20–30 min
at 4
 
 
 
C in the dark. After washing cells with PBS/1% BSA
 
Table I.
 
Patients’ Sex, Age, and Duration of Each Autoimmune 
Endocrine Disease
 
a
 
Patient Sex Age
Addison’s
disease
Type I
diabetes
Autoimmune
thyroiditis
Gonadal
insufficiency
 
yr yr yr yr yr
 
1 F 30 1 – 12 –
2F 3 3 – 2 4 2 4 –
3 F 35 24 – 21 19
4 F 62 15 23 15 –
5 F 31 17 – 17 –
6F 3 0 8 – 8 –
7F 3 4 5 – 8 –
8 M 63 31 31 – –
1F 3 6 – – 3 –
2F 4 3 – 5 – –
3M 3 4 3 – – –
4F 2 2 – 8 – –
5F 5 1 – – 1 –
6M 4 0 7 – – –
7 F 30 – 26 – –
8 F 65 – 41 – –
 
a
 
APS-II patients (top). Control patients with single autoimmune endo-
crinopathies (bottom). Refer to the 
 
Study Subjects
 
 section of Materials
and Methods for further clinical details.
F, female; M, male. 
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(Sigma-Aldrich), cells were analyzed by flow cytometry. In all
experiments, gates were set so that negative controls stained 
 
 
 
1%
false positive cells.
 
Quantification of Early Apoptosis, Late Apoptosis, and Necrosis.
 
2.5 
 
 
 
 10
 
4
 
 CD4
 
 
 
 CD25
 
 
 
 and CD25
 
 
 
 cells were kept in culture
medium alone or supplemented with 10 U/ml of IL-2 for 2 d in
flat-bottom microtiter plates. Features of cell death were detected
by staining with FITC-conjugated annexin V in propidium io-
dide–containing staining buffer for 30 min at 4
 
 
 
C in the dark.
After flow cytometric analysis, four populations can be distin-
guished as follows: viable cells (annexin V negative and pro-
pidium iodide negative), early apoptotic cells (annexin V positive
and propidium iodide negative), late apoptotic cells (annexin V
positive and propidium iodide intermediate), and primary ne-
crotic cells (propidium iodide highly positive).
 
Semiquantitative Analysis of mRNA by RT-PCR. 
 
To analyze
the expression of human FOXP3 transcripts, 5 
 
 
 
 10
 
5
 
 CD4
 
 
 
CD25
 
 
 
 and CD25
 
 
 
 T cells were lysed immediately after isola-
tion. Total RNA was isolated using an RNeasy Mini kit™
(QIAGEN) as described previously (23). Messenger RNA was
reverse transcribed with oligo(dT) primers and amplified with
gene-specific primers. Primer sequences can be obtained from the
authors upon request. cDNA was amplified for 28 and 35 cycles
for FOXP3, and for 21 and 28 cycles for GAPDH.
 
Statistical Analyses. 
 
One-way analysis of variance with Tukey-
Kramer posttest and Wilcoxon matched-pairs signed ranks test
were performed using InStat™ software (version 3.00; GraphPad).
 
Results and Discussion
 
Quantification and Functional Characterization of CD4
 
 
 
CD25
 
 
 
 T Cells in Peripheral Blood. 
 
First, we isolated
PBMCs from normal healthy donors, APS-II, and control
patients, and quantified CD25 expression on CD4
 
 
 
 T cells.
The average percentage of CD4
 
 
 
 CD25
 
 
 
 T cells from our
normal donors was 9.3% compatible with previous counts
of human T
 
reg
 
 numbers in healthy persons. The quantity
of this subpopulation of CD4
 
 
 
 T cells was similar in pa-
tients with APS-II (9.0% on average), but generally re-
duced in blood from control patients (3.0% on average).
No CD4 lymphopenia was noted in either study group.
Following quantities over time, we found persistently re-
duced levels of T
 
reg
 
 numbers from control patients (un-
published data), pointing toward a possible intrinsic defect
in keeping normal quantities of natural T
 
regs
 
 in patients
with single endocrinopathies.
Figure 1. Functional analysis of CD4 
CD25  Tregs. (A and B) Background proliferation
of irradiated feeder cells (white bars), proliferation
of CD4  CD25  responder cells (black bars),
CD4  CD25  T regs (crosshatched bars), or of
both populations added in a 1:1 ratio (diago-
nally striped bars) from normal healthy donors
(n   10), APS-II (n   8), or control patients
(n   8) in response to OKT-3 or PHA stimu-
lation, respectively. p-values for OKT-3 stimu-
lation were as follows (A): **   0.0078 (normal
donors), **   0.0078 (control patients); and for
PHA stimulation: **   0.002 (normal donors),
**   0.0078 (control patients). (C) Percentages
of inhibition of proliferation of CD4  CD25 
responder cells by CD4  CD25  Tregs at a 1:1
ratio from normal healthy donors (n    10),
APS-II (n   8), or control patients (n   8),
respectively. Values were calculated from pro-
liferation assays with PHA stimulation. **, P  
0.01; *, P   0.05. (D) Inhibition of prolifera-
tion of CD4  CD25  responder cells by CD4 
CD25  T regs at different ratios (responders to
suppressors) from normal donors (gray triangles,
n   7), APS-II (black squares, n   6), or control
patients (white circles, n   6). Error bars represent
SEM. (E) Percentages of inhibition of prolifera-
tion of CD4  CD25  responder cells by CD4 
CD25  Tregs at a 1:1 ratio from a representative
normal donor (gray triangles), APS-II (black
squares), or control patient (white circles) over
a period of  1 yr. Values were calculated from
proliferation assays with OKT-3 stimulation.
Blood drawn from each study subject (indicated
by each time point) were separated by several
weeks to months. (F) Determination of the origin
of defective suppression. Percentages of inhibition
of proliferation of CD4  CD25  responder
cells by CD4  CD25  Tregs at a 1:1 ratio. Re-
sponders and suppressors from either normal donors or APS-II patients were mixed in the following combinations: APS responders   APS suppressors
(white bar), APS responders   normal donor suppressors (black bar), normal donor responders   normal donor suppressors (crosshatched), and normal
donor responders   APS suppressors (diagonally striped bar). Each bar represents an average of three independent experiments. Error bars represent SEM.T Suppressor Cell Defect In Polyglandular Autoimmunity 1288
To functionally analyze Tregs, we separated CD4 
CD25  and CD25  T cell fractions. Mixing both pop-
ulations from normal donors at a ratio of 1:1 induced
profound suppression of CD25  T cell proliferation in
response to OKT-3 (Fig. 1 A) or PHA (Fig. 1 B), re-
spectively. Similar results were obtained from cells of
control patients (Fig. 1, A and B). Strikingly, the suppres-
sive capacity of CD4  CD25  T cells from APS-II patients
was consistently impaired (Fig. 1, A and B). Tregs from
APS-II patients were also dysfunctional after costimulation
with soluble anti-CD28 plus OKT-3 compared with nor-
mal donors or control patients (unpublished data). Com-
paring percentages of inhibition of proliferation from each
study subject indicated that coculture of cells from some
APS-II patients even induced proliferation instead of inhi-
bition (Fig. 1 C), reflecting a complete loss of suppressor
function. The defect was partially reversible if higher num-
bers of Tregs were titrated to responders (Fig. 1 D), whereas
Tregs from normal donors and control patients strongly sup-
pressed in a cell number–dependent manner (Fig. 1 D). To
test whether Tregs from APS-II patients were still responsive
to IL-2, we added IL-2 to the cocultures in addition to
OKT-3 stimulation. Tregs were not hyporesponsive any
longer, and inhibition of proliferation was abolished in all
three groups (unpublished data). To examine if lack of sup-
pressor function is also stable over time, we performed
identical coculture experiments at several time points in
three subjects. Loss of suppressor function in APS-II as well
as intact function in normal donor and control patient were
conserved over a time period of several months in each of
the three study subjects (Fig. 1 E).
Next, we wanted to dissect defective suppressor cell
function versus responder cell resistance in APS-II patients
because defective regulation seen in the coculture assays
from cells of APS-II patients could theoretically be attrib-
uted to either impaired suppressor function of Tregs (as pro-
posed) or resistance of responder cells to Treg-mediated sup-
pression (24). To test both possibilities, we mixed responder
cells from APS-II patients with Tregs from normal donors
and vice versa (Fig. 1 F). Although Tregs from normal donors
appropriately suppressed responders from APS-II patients,
APS-II Tregs could obviously not inhibit proliferation of re-
sponder cells from normal donors (Fig. 1 F), indicating that
impaired suppression of proliferation is clearly due to defec-
tive Tregs instead of resistance of responders.
Finally, we also studied suppressor function in the CD4 
CD25high compartment of two representative patients with
APS-II (one with consistent impairment and one with
intact Treg function). FACS®-sorted, CD25high-expressing
CD4  T cells from the patient with dysfunctional Tregs
were still impaired in their suppressor function compared
with normal donor cells (32.4% vs. 78.8% for inhibition of
PHA-induced proliferation and 18.6% vs. 68.4% for inhibi-
Figure 2. (A) Phenotypic analysis of CD4  CD25  Tregs. Cell surface
expression of CTLA-4, TGF , and HLA-DR on CD4  CD25  Tregs after
isolation from normal donors, APS-II, or control patients. Thin lines repre-
sent isotype controls. The data shown are representative of at least two
independent experiments; values of each graph represent the percentage
of positive cells. (B–D) Rate of apoptosis of CD4  CD25  responder
cells (Responder) and CD4  CD25  Tregs (Suppressor) from normal donors
(B), APS-II (C), and control patients (D) after 2 d of culture in medium
alone versus medium supplemented with IL-2. Four populations can be
distinguished as described in Materials and Methods. The data shown are
representative of at least three independent experiments; values represent
the percentage of positive cells.Kriegel et al. Brief Definitive Report 1289
tion of OKT-3–induced proliferation) or APS-II cells from
the patient with intact Tregs (unpublished data). In all three
subjects, sorted cells rendered approximately similar results
as MACS-separated total CD25  cells.
Phenotypic Characterization of CD4  CD25  T Cells.
To further investigate the profound defect of Tregs from
APS-II patients, we wanted to examine possible pheno-
typic changes of the Tregs. Surface CTLA-4 and membrane-
bound TGF  have been described as possible mediators of
murine Treg function (2, 17, 25). Although we could con-
firm expression of these molecules on human Tregs (Fig. 2
A), we did not find significant changes of surface expression
of CTLA-4 or TGF  on APS-II Tregs compared with nor-
mal donors or control patients (Fig. 2 A). Also, the number
of Tregs expressing these markers did not differ between
groups (Fig. 2 A). Although not significantly expressed on
resting Tregs, GITR is up-regulated upon activation and
transmits negative signals into murine Tregs (26, 27). There-
fore, we also wanted to determine if abnormally elevated
levels of GITR on resting Tregs from patients with APS-II
might be measurable. However, we did not detect signifi-
cant expression of GITR on Tregs from any study group
(unpublished data).
Besides these functionally relevant molecules, Tregs ex-
press several activation markers. We thought that one of
them, HLA-DR, would be of special interest. Aside from
being expressed on activated human T cells, HLA-DR
is predominantly on the surface of Tregs compared with
CD25  T cells (15). Because MHC class II molecules on T
cells have been shown to be involved in T–T interactions,
causing anergy in the target cells (28), we have chosen to
screen for alterations in HLA-DR expression or density on
Tregs. However, no significant differences have been found
between Tregs from normal donors, APS-II, or control pa-
tients (Fig. 2 A). Similarly, analysis of CD28 and PD-1
(two important members of the costimulatory family), and
of Fas (CD95) also revealed no differences (unpublished
data). Because some phenotypic alterations might not be-
come apparent before triggering cells, we also measured
GITR and CTLA-4 on Tregs after activation. To this end,
we stimulated cells with plate-bound OKT-3 and IL-2 for
7 d. But, again, no significant differences were detectable
between groups (unpublished data).
Apoptosis of CD4  CD25  and CD25  T Cells after
Growth Factor Withdrawal.  Taams et al. demonstrated that
human Tregs rapidly die in vitro, whereas CD4  CD25  T
cells are substantially less susceptible to growth factor with-
drawal (14). Adding IL-2 to the culture could increase the
survival rate of Tregs to a limited extent (14). To exclude
the possibility that Tregs from APS-II or control patients
would die faster than normal donor Tregs, we measured the
rate of apoptosis after 2 d of culture in medium with or
without IL-2 (Fig. 2, B–D). Although we could confirm
that suppressor cells die more quickly than responder cells
in vitro (Fig. 2 B), we did not detect an increase of cell
death in APS-II (Fig. 2 C) or control patient cells (Fig. 2
D). This was evident for early, late apoptotic, or necrotic
cell death (Fig. 2, B–D). Furthermore, IL-2 could rescue
both CD25  and CD25  cells to a limited extent in our
system (Fig. 2 B), but no lack of rescue was noted in cells
from APS-II or control patients (Fig. 2, C and D).
The pathogenesis of APS-II is largely unknown, and a
common pathogenetic mechanism responsible for the com-
bined occurrence of multiple endocrinopathies in these
patients has not been elucidated. We found defective sup-
pressor function of Tregs from the majority of patients with
APS-II, whereas we could not detect overt quantitative or
phenotypic abnormalities in Tregs from these patients. In ad-
dition, their apoptotic behavior to growth factor withdrawal
was intact. However, an increase of contamination with re-
cently activated CD25  T cells could be excluded for the
following reasons. Any study subject with signs or symp-
toms of infection was excluded. Autoimmune endocrine
diseases do not go along with systemic immune activation
due to their organ-specific nature. APS-II patients did not
exhibit increased numbers of peripheral CD25  T cells
compared with normal donors. We also confirmed suppres-
sor dysfunction by FACS®-sorted CD25high-expressing Tregs.
Furthermore, Tregs from all study groups had similar pheno-
typic features and apoptotic behaviors. Tregs from APS-II
patients showed identical functional features as Tregs from
normal donors or control patients with the exception of de-
fective suppressor function (i.e., they showed similar in vitro
anergy and responsiveness to IL-2). Finally, in preliminary
experiments, we semi-quantified two samples of FOXP3
messenger RNA from APS-II Tregs. Both contained similar
levels of FOXP3 transcripts compared with normal donor
Tregs (Fig. 3) despite defective suppressor function, clearly
indicating that true Tregs were dysfunctional. Interestingly,
Tregs from one additional patient exhibited reduced levels of
FOXP3. However, further detailed experiments are needed
to confirm and extend this finding.
Defective Treg function in humans with APS-II has wide
implications for autoimmunity in general. Although deple-
tion of murine CD4  CD25  T cells has initially been
demonstrated to cause predominantly polyglandular au-
toimmunity (18), functional Tregs seem to also prevent dis-
ease in various other murine models (2). Therefore, defec-
tive human Treg cell function might also modulate other
disease states, such as multiple sclerosis or systemic lupus
erythematosus. With regard to APS-II, our data provide
Figure 3. Levels of FOXP3 transcripts. FOXP3 messenger RNA was
detected after RT-PCR in CD4  CD25  Tregs (S) or CD25  responder
cells (R). Samples from two normal donors and APS-II patients, respec-
tively, are shown. Amounts of GAPDH transcripts are shown (bottom).T Suppressor Cell Defect In Polyglandular Autoimmunity 1290
first advances in understanding the pathogenesis of this syn-
drome. Because strategies intervening early in the disease
process have been proven to be effective in organ-specific
autoimmunity (29), this might be of future importance.
In summary, we have demonstrated persistent defec-
tive suppressor activity of CD4  CD25  T regs in APS-II,
thereby contributing to a better understanding of the patho-
genesis of this syndrome and possibly autoimmunity in gen-
eral. Once molecular mechanisms of suppressor function are
better delineated, manipulations of human Tregs may even-
tually allow improvement of immunomodulatory strategies
in diseases with impaired suppressor function.
We would like to thank all study subjects for their participation.
We are also grateful to Dr. W. Baum for assistance of the hybrid-
oma antibody elution, to E. Scherb for excellent technical support,
and to Bristol Myers Squibb for providing the anti-CD28 mAbs.
This work was supported by grants from the Interdisciplinary
Center for Clinical Research (IZKF C13) and the German
Research Association (Sonderforschungsbereich 263) to H.-M.
Lorenz, and from the ELAN Fonds fuer Forschung und Lehre
(grant 01.11.20.1) of the University of Erlangen-Nuremberg to
M. A. Kriegel and H.-M. Lorenz.
Submitted: 11 December 2003
Accepted: 26 March 2004
References
1. Walker, L.S., and A.K. Abbas. 2002. The enemy within:
keeping self-reactive T cells at bay in the periphery. Nat.
Rev. Immunol. 2:11–19.
2. Shevach, E.M. 2002. CD4  CD25  suppressor T cells:
more questions than answers. Nat. Rev. Immunol. 2:389–400.
3. Yamazaki, S., T. Iyoda, K. Tarbell, K. Olson, K. Velinzon,
K. Inaba, and R.M. Steinman. 2003. Direct expansion of
functional CD25  CD4  regulatory T cells by antigen-pro-
cessing dendritic cells. J. Exp. Med. 198:235–247.
4. Maloy, K.J., L. Salaun, R. Cahill, G. Dougan, N.J. Saunders,
and F. Powrie. 2003. CD4 CD25  T(R) cells suppress in-
nate immune pathology through cytokine-dependent mech-
anisms. J. Exp. Med. 197:111–119.
5. Levings, M.K., R. Sangregorio, and M.G. Roncarolo. 2001.
Human CD25  CD4  T regulatory cells suppress naive and
memory T cell proliferation and can be expanded in vitro
without loss of function. J. Exp. Med. 193:1295–1302.
6. Fontenot, J.D., M.A. Gavin, and A.Y. Rudensky. 2003.
Foxp3 programs the development and function of CD4 
CD25  regulatory T cells. Nat. Immunol. 4:330–336.
7. Hori, S., T. Nomura, and S. Sakaguchi. 2003. Control of
regulatory T cell development by the transcription factor
Foxp3. Science. 299:1057–1061.
8. Khattri, R., T. Cox, S.A. Yasayko, and F. Ramsdell. 2003.
An essential role for Scurfin in CD4 CD25  T regulatory
cells. Nat. Immunol. 4:337–342.
9. Bennett, C.L., J. Christie, F. Ramsdell, M.E. Brunkow, P.J.
Ferguson, L. Whitesell, T.E. Kelly, F.T. Saulsbury, P.F.
Chance, and H.D. Ochs. 2001. The immune dysregulation,
polyendocrinopathy, enteropathy, X-linked syndrome (IPEX)
is caused by mutations of FOXP3. Nat. Genet. 27:20–21.
10. Dieckmann, D., C.H. Bruett, H. Ploettner, M.B. Lutz, and
G. Schuler. 2002. Human CD4 CD25  regulatory, contact-
dependent T cells induce interleukin 10–producing, contact-
independent type 1–like regulatory T cells. J. Exp. Med. 196:
247–253.
11. Dieckmann, D., H. Plottner, S. Berchtold, T. Berger, and G.
Schuler. 2001. Ex vivo isolation and characterization of
CD4 CD25  T cells with regulatory properties from human
blood. J. Exp. Med. 193:1303–1310.
12. Jonuleit, H., E. Schmitt, M. Stassen, A. Tuettenberg, J.
Knop, and A.H. Enk. 2001. Identification and functional
characterization of human CD4 CD25  T cells with regula-
tory properties isolated from peripheral blood. J. Exp. Med.
193:1285–1294.
13. Jonuleit, H., E. Schmitt, H. Kakirman, M. Stassen, J. Knop,
and A.H. Enk. 2002. Infectious tolerance: human CD25 
regulatory T cells convey suppressor activity to conventional
CD4  T helper cells. J. Exp. Med. 196:255–260.
14. Taams, L.S., J. Smith, M.H. Rustin, M. Salmon, L.W.
Poulter, and A.N. Akbar. 2001. Human anergic/suppressive
CD4( )CD25( ) T cells: a highly differentiated and apop-
tosis-prone population. Eur. J. Immunol. 31:1122–1131.
15. Baecher-Allan, C., J.A. Brown, G.J. Freeman, and D.A.
Hafler. 2001. Cd4( )cd25(high) regulatory cells in human
peripheral blood. J. Immunol. 167:1245–1253.
16. Annunziato, F., L. Cosmi, F. Liotta, E. Lazzeri, R. Manetti, V.
Vanini, P. Romagnani, E. Maggi, and S. Romagnani. 2002.
Phenotype, localization, and mechanism of suppression of
CD4 CD25  human thymocytes. J. Exp. Med. 196:379–387.
17. Sakaguchi, S., N. Sakaguchi, J. Shimizu, S. Yamazaki, T.
Sakihama, M. Itoh, Y. Kuniyasu, T. Nomura, M. Toda, and
T. Takahashi. 2001. Immunologic tolerance maintained by
CD25  CD4  regulatory T cells: their common role in
controlling autoimmunity, tumor immunity, and transplanta-
tion tolerance. Immunol. Rev. 182:18–32.
18. Sakaguchi, S., N. Sakaguchi, M. Asano, M. Itoh, and M.
Toda. 1995. Immunologic self-tolerance maintained by acti-
vated T cells expressing IL-2 receptor alpha-chains (CD25).
Breakdown of a single mechanism of self-tolerance causes
various autoimmune diseases. J. Immunol. 155:1151–1164.
19. Devendra, D., and G.S. Eisenbarth. 2003. 17. Immunologic
endocrine disorders. J. Allergy Clin. Immunol. 111:S624–S636.
20. Anderson, M.S. 2002. Autoimmune endocrine disease. Curr.
Opin. Immunol. 14:760–764.
21. Anderson, M.S., E.S. Venanzi, L. Klein, Z. Chen, S.P.
Berzins, S.J. Turley, H. von Boehmer, R. Bronson, A. Dier-
ich, C. Benoist, and D. Mathis. 2002. Projection of an im-
munological self shadow within the thymus by the aire pro-
tein. Science. 298:1395–1401.
22. Wallaschofski, H., A. Meyer, U. Tuschy, and T. Lohmann.
2003. HLA-DQA1*0301-associated susceptibility for au-
toimmune polyglandular syndrome type II and III. Horm.
Metab. Res. 35:120–124.
23. Blank, N., M. Kriegel, T. Hieronymus, T. Geiler, S. Wink-
ler, J.R. Kalden, and H.M. Lorenz. 2001. CD45 tyrosine
phosphatase controls common gamma-chain cytokine-medi-
ated STAT and extracellular signal-related kinase phosphory-
lation in activated human lymphoblasts: inhibition of prolif-
eration without induction of apoptosis. J. Immunol. 166:
6034–6040.
24. Pasare, C., and R. Medzhitov. 2003. Toll pathway-depen-
dent blockade of CD4 CD25  T cell-mediated suppression
by dendritic cells. Science. 299:1033–1036.
25. Nakamura, K., A. Kitani, and W. Strober. 2001. Cell con-
tact–dependent immunosuppression by CD4 CD25  regu-Kriegel et al. Brief Definitive Report 1291
latory T cells is mediated by cell surface–bound transforming
growth factor  . J. Exp. Med. 194:629–644.
26. McHugh, R.S., M.J. Whitters, C.A. Piccirillo, D.A. Young,
E.M. Shevach, M. Collins, and M.C. Byrne. 2002.
CD4( )CD25( ) immunoregulatory T cells: gene expres-
sion analysis reveals a functional role for the glucocorticoid-
induced TNF receptor. Immunity. 16:311–323.
27. Shimizu, J., S. Yamazaki, T. Takahashi, Y. Ishida, and S.
Sakaguchi. 2002. Stimulation of CD25( )CD4( ) regula-
tory T cells through GITR breaks immunological self-toler-
ance. Nat. Immunol. 3:135–142.
28. LaSalle, J.M., P.J. Tolentino, G.J. Freeman, L.M. Nadler,
and D.A. Hafler. 1992. Early signaling defects in human T
cells anergized by T cell presentation of autoantigen. J. Exp.
Med. 176:177–186.
29. Herold, K.C., W. Hagopian, J.A. Auger, E. Poumian-Ruiz,
L. Taylor, D. Donaldson, S.E. Gitelman, D.M. Harlan, D.
Xu, R.A. Zivin, and J.A. Bluestone. 2002. Anti-CD3 mono-
clonal antibody in new-onset type 1 diabetes mellitus. N.
Engl. J. Med. 346:1692–1698.